Giovanna Giorgiani

Giovanna Giorgiani

Auto-generated profile, based on publicly available information

Giovanna Giorgiani

Oncoematologia Pediatrica, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2003 in Blood
Verified
Journal Article
Closed access
PDF file
SGSebastian Giebel
Sebastian Giebel
FLFranco Locatelli
Franco Locatelli
TLTeresa Lamparelli
Teresa Lamparelli
AVAndrea Velardi
Andrea Velardi
SDStella Davies
Stella Davies
JHJerzy Holowiecki
Jerzy Holowiecki
Killer immunoglobulin-like receptor (KIR) ligand incompatibility in the graft-versus-host direction was demonstrated to be associated with improved outcome in patients given haploidentical, T-cell–depleted hematopoietic stem cell transplants (HSCTs). The goal of this study was to evaluate whether that observation could be generalized for patients receiving unmanipulated HSCTs from unrelated donors (URD). One hundred thirty patients with hematologic malignancies entered the study. Graft-versus-host disease (GVHD) prophylaxis was uniform and consisted of cyclosporin, short-term methotrexate, and pretransplantation antithymocyte globulin (ATG). Patients were divided into those with (n = 20) and those without (n = 110) KIR ligand incompatibility with respect to their donors. At 4.5 years patients with KIR ligand incompatibility had higher probability of overall survival (87% versus 48%, P = .006) and disease-free survival (87% versus 39%, P = .0007) compared with those without KIR ligand incompatibility. Transplant-related mortality for the 2 groups equaled 6% and 40% (P = .01), respectively. Relapse rates for patients receiving transplants from a donor with or without KIR ligand incompatibility were 6% and 21%, respectively (P = .07). All patients with myeloid malignancies receiving transplants from KIR ligand–disparate donors (n = 13) are alive and disease free. These data indicate that natural killer (NK) cell alloreactivity is associated with better outcome after URD-HSC transplantation when ATG is used as part of GVHD prophylaxis.

31 August 2013 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
LBLynne M. Ball
Lynne M. Ball
MBMaria E. Bernardo
Maria E. Bernardo
HRHelene Roelofs
Helene Roelofs
MTMaarten J. D. van Tol
Maarten J. D. van Tol
BCBenedetta Contoli
Benedetta Contoli
FLFranco Locatelli
Franco Locatelli
Summary: Mesenchymal stromal cell (MSC) infusions have been reported to be effective in patients with steroid‐refractory, acute graft‐versus‐host disease (aGvHD) but comprehensive data on paediatric patients are limited. We retrospectively analysed a cohort of 37 children (aged 3 months‐17 years) treated with MSCs for steroid‐refractory grade III–IV aGvHD. All patients but three received multiple MSC infusions. Complete response (CR) was observed in 24 children (65%), while 13 children had either partial (n = 8) or no response (n = 5). Cumulative incidence of transplantation‐related mortality (TRM) in patients who did or did not achieve CR was 17% and 69%, respectively (P = 0·001). After a median follow‐up of 2·9 years, overall survival (OS) was 37%; it was 65% vs. 0% in patients who did or did not achieve CR, respectively (P = 0·001). The median time from starting steroids for GvHD treatment to first MSC infusion was 13 d (range 5–85). Children treated between 5 and 12 d after steroid initiation showed a trend for better OS (56%) and lower TRM (17%) as compared with patients receiving MSCs 13–85 d after steroids (25% and 53%, respectively; P = 0·22 and 0·06, respectively). Multiple MSC infusions are safe and effective for children with steroid‐refractory aGvHD, especially when employed early in the disease course.

12 July 2012 in Blood
Verified
Journal Article
Closed access
PDF file
MBMaria Ester Bernardo
Maria Ester Bernardo
EPEugenia Piras
Eugenia Piras
AVAdriana Vacca
Adriana Vacca
GGGiovanna Giorgiani
Giovanna Giorgiani
MZMarco Zecca
Marco Zecca
FLFranco Locatelli
Franco Locatelli
Sixty thalassemia patients (median age, 7 years; range, 1-37) underwent allogeneic hematopoietic stem cell transplantation (HSCT) after a preparation combining thiotepa, treosulfan, and fludarabine. Before HSCT, 27 children were assigned to risk class 1 of the Pesaro classification, 17 to class 2, and 4 to class 3; 12 patients were adults. Twenty patients were transplanted from an HLA-identical sibling and 40 from an unrelated donor. The cumulative incidence of graft failure and transplantation-related mortality was 9% and 7%, respectively. Eight patients experienced grade II-IV acute GVHD, the cumulative incidence being 14%. Among 56 patients at risk, 1 developed limited chronic GVHD. With a median follow-up of 36 months (range, 4-72), the 5-year probability of survival and thalassemia-free survival are 93% and 84%, respectively. Neither the class of risk nor the donor used influenced outcome. This treosulfan-based preparation proved to be safe and effective for thalassemia patients given allogeneic HSCT.

20 June 2003 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
CMChiara Messina
Chiara Messina
FLFranco Locatelli
Franco Locatelli
ELEdoardo Lanino
Edoardo Lanino
CUCornelio Uderzo
Cornelio Uderzo
GZGraziella Zacchello
Graziella Zacchello
RDRoberto Dall'Amico
Roberto Dall'Amico
Summary.This study aimed to ascertain whether extracorporeal photochemotherapy (ECP) is an effective treatment for paediatric patients with refractory graft‐versus‐host disease (GVHD). From January 1992 to December 2000, 77 children (median age 8·6 years) with either acute (n = 33) or chronic (n = 44) GVHD, resistant to conventional immunosuppressive therapy, were treated with ECP in four Italian paediatric hospitals. After ECP, acute GVHD involving skin, liver and gut responded completely in 76%, 60% and 75% of patients respectively. The 5‐year overall survival was 69% for responding patientsvs12% for non‐responders (P = 0·001). Among the 44 children with chronic GVHD, 15 (44%) showed a complete response and 10 (29%) a significant improvement after ECP. The 5‐year overall survival was 96% for respondersvs58% for non‐responders (P = 0·04). Our results suggest that ECP is an effective treatment that may be useful in paediatric patients with either acute or chronic GVHD who have failed to respond to standard immunosuppressive therapy.

1 October 2001 in Transfusion
Verified
Journal Article
Closed access
PDF file
LSLaura Salvaneschi
Laura Salvaneschi
CPCesare Perotti
Cesare Perotti
MZMarco Zecca
Marco Zecca
SBStefano Bernuzzi
Stefano Bernuzzi
GVGianluca Viarengo
Gianluca Viarengo
FLFranco Locatelli
Franco Locatelli

1 March 2001 in Experimental Hematology
Verified
Journal Article
Closed access
AMAntonia Moretta
Antonia Moretta
RMRita Maccario
Rita Maccario
Franca FagioliFranca Fagioli
Franca Fagioli
EGEugenia Giraldi
Eugenia Giraldi
Alessandro BuscaAlessandro Busca
Alessandro Busca
FLFranco Locatelli
Franco Locatelli